替莫唑胺联合放疗治疗神经胶质瘤术后患者的临床疗效及安全性评估

Clinical efficacy and safety evaluation of temozolomide combined with radiotherapy for postoperative patients with glioma

目的探讨替莫唑胺联合放疗治疗神经胶质瘤术后患者的临床疗效,并分析其安全性。方法以我院2016年4月~2020年5月收治的96例神经胶质瘤术后患者为研究对象,随机分为试验组和对照组,每组48例。对照组采用三维适形放射治疗,试验组在对照组的基础上联合替莫唑胺治疗,比较两组患者的临床疗效、生存质量评分和不良反应情况,并对两组患者随访1年的生存状态进行分析。结果试验组患者的治疗有效率为91.67%,对照组为72.92%,两组比较差异有统计学意义(P<0.05)。治疗后,试验组患者的生活质量改善明显优于对照组,不良反应发生率低于对照组,差异均有统计学意义(均P<0.05)。两组患者的半年生存率和1年生存率比较,试验组均高于对照组,差异均有统计学意义(均P<0.05)。结论替莫唑胺联合放疗用于神经胶质瘤术后患者的临床疗效优于单纯放疗,且不良反应低,安全性高。

Objective To explore the clinical effect of Temozolomide Combined with radiotherapy in the treatment of postoperative patients with glioma,analyze its safety and provide reference for clinical medication.Methods 96 postoperative glioma patients were enrolled from April 2016 to May 2020,and were divided into test group and control group,with 48 patients in each group.The control group patients received three-dimensional conformal radiotherapy,while the patients in the experimental group were treated with temozolomide in combination on the basis of the control group.The treatment effects,quality of life scores and adverse reactions of the two groups were compared.The two groups were followed up for one year.The patient's survival status is analyzed.Results The treatment effective rate of patients in the experimental group was 91.67%,higher than72.92%of the control group was.The total effective rate of the treatment in the experimental group was higher than that of the control group,and the difference was statistically significant(P<0.05).After the two groups of glioma patients were treated in different ways,the quality of life of the experimental group was significantly better than that of the control group(P<0.05).The total incidence of adverse reactions after drug treatment in the experimental group was lower than that of the control group.The survival rate and one-year survival rate were higher than those of the control group,and the differences were statistically significant(P<0.05 for both).Conclusion Temozolomide Combined with radiotherapy for postoperative patients with gliomas is superior to radiotherapy alone,with low adverse reactions and high safety.